A study in HCC demonstrated that NK cells expressing DNR II combined with CARs targeting GPC3 or AFP could effectively resist TGF-β-mediated inhibition and enhance the tumor-killing capability of CAR-NK cells (120). The gene discussed is TGFB1; the disease is neoplasm.